CASI Pharmaceuticals Inc logo

CASI - CASI Pharmaceuticals Inc Share Price

$1.53 -0.0  -1.3%

Last Trade - 9:00pm

Small Cap
Market Cap £149.4m
Enterprise Value £130.1m
Revenue £7.94m
Position in Universe 3778th / 6412
Unlock CASI Revenue
Relative Strength (%)
1m -6.97%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -57.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.024 0.048 0.000 0.000 0.000 4.13 11.4 21.6 +180.6%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CASI Pharmaceuticals Inc revenues increased from $0K to $6.1M. Net loss applicable to common stockholders decreased 27% to $17.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative - Balancing v decrease of 54% to $4.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CASI Revenue Unlock CASI Revenue

Net Income

CASI Net Income Unlock CASI Revenue

Normalised EPS

CASI Normalised EPS Unlock CASI Revenue

PE Ratio Range

CASI PE Ratio Range Unlock CASI Revenue

Dividend Yield Range

CASI Dividend Yield Range Unlock CASI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CASI EPS Forecasts Unlock CASI Revenue
Profile Summary

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 18, 1991
Public Since June 12, 1996
No. of Shareholders: 290
No. of Employees: 125
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 123,943,829
Free Float (0.0%)
Eligible for
CASI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CASI
Upcoming Events for CASI
Tuesday 10th November, 2020 Estimate
Q3 2020 CASI Pharmaceuticals Inc Earnings Release
Monday 15th March, 2021 Estimate
Q4 2020 CASI Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for CASI Pharmaceuticals Inc
What is the CASI Pharmaceuticals Inc share price?

As of 9:00pm, shares in CASI Pharmaceuticals Inc are trading at $1.53, giving the company a market capitalisation of £149.4m. This share price information is delayed by 15 minutes.

How has the CASI Pharmaceuticals Inc share price performed this year?

Shares in CASI Pharmaceuticals Inc are currently trading at $1.53 and the price has moved by -53.59% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CASI Pharmaceuticals Inc price has moved by -59.29% over the past year.

What are the analyst and broker recommendations for CASI Pharmaceuticals Inc?

Of the analysts with advisory recommendations for CASI Pharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CASI Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will CASI Pharmaceuticals Inc next release its financial results?

CASI Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CASI Pharmaceuticals Inc dividend yield?

CASI Pharmaceuticals Inc does not currently pay a dividend.

Does CASI Pharmaceuticals Inc pay a dividend?

CASI Pharmaceuticals Inc does not currently pay a dividend.

When does CASI Pharmaceuticals Inc next pay dividends?

CASI Pharmaceuticals Inc does not currently pay a dividend.

How do I buy CASI Pharmaceuticals Inc shares?

To buy shares in CASI Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CASI Pharmaceuticals Inc?

Shares in CASI Pharmaceuticals Inc are currently trading at $1.53, giving the company a market capitalisation of £149.4m.

Where are CASI Pharmaceuticals Inc shares listed? Where are CASI Pharmaceuticals Inc shares listed?

Here are the trading details for CASI Pharmaceuticals Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CASI
What kind of share is CASI Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, CASI Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CASI Pharmaceuticals Inc share price forecast 2020?

Shares in CASI Pharmaceuticals Inc are currently priced at $1.53. At that level they are trading at 0.106% discount to the analyst consensus target price of 0.00.

Analysts covering CASI Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.253 for the next financial year.

How can I tell whether the CASI Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CASI Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -40.06%. At the current price of $1.53, shares in CASI Pharmaceuticals Inc are trading at -29.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CASI Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for CASI Pharmaceuticals Inc.

Who are the key directors of CASI Pharmaceuticals Inc?

CASI Pharmaceuticals Inc's management team is headed by:

Wei-Wu He - CHM
James Huang - IND
Y. Alexander Wu - IND
Franklin Salisbury - IND
Rajesh Shrotriya - IND
Alexander Zukiwski - OTH
Wei Zhang - PRE
Quan Zhou - IND
Who are the major shareholders of CASI Pharmaceuticals Inc?

Here are the top five shareholders of CASI Pharmaceuticals Inc based on the size of their shareholding:

He (Wei-Wu) Individual Investor
Percentage owned: 10.34% (12.8m shares)
Sparkle Byte Ltd Corporation
Percentage owned: 8.23% (10.2m shares)
Li (Dapeng) Individual Investor
Percentage owned: 7.56% (9.36m shares)
Spectrum Pharmaceuticals, Inc. Corporation
Percentage owned: 7.45% (9.23m shares)
Wealth Strategy Holding Ltd Corporation
Percentage owned: 7.33% (9.09m shares)
Similar to CASI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.